- Home
- RDAC vs SPRO Comparison
RDAC vs SPRO Comparison
Compare RDAC & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDAC
- SPRO
- Stock Information
- Founded
- RDAC 2024
- SPRO 2013
- Country
- RDAC China
- SPRO United States
- Employees
- RDAC N/A
- SPRO 46
- Industry
- RDAC
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- RDAC
- SPRO Health Care
- Exchange
- RDAC NYSE
- SPRO Nasdaq
- Market Cap
- RDAC 75.2M
- SPRO 49.6M
- IPO Year
- RDAC 2024
- SPRO 2017
- Fundamental
- Price
- RDAC $10.05
- SPRO $0.91
- Analyst Decision
- RDAC
- SPRO Buy
- Analyst Count
- RDAC 0
- SPRO 4
- Target Price
- RDAC N/A
- SPRO $5.00
- AVG Volume (30 Days)
- RDAC 1.4K
- SPRO 292.3K
- Earning Date
- RDAC 01-01-0001
- SPRO 03-12-2025
- Dividend Yield
- RDAC N/A
- SPRO N/A
- EPS Growth
- RDAC N/A
- SPRO N/A
- EPS
- RDAC N/A
- SPRO 0.06
- Revenue
- RDAC N/A
- SPRO $106,455,000.00
- Revenue This Year
- RDAC N/A
- SPRO N/A
- Revenue Next Year
- RDAC N/A
- SPRO N/A
- P/E Ratio
- RDAC N/A
- SPRO $14.06
- Revenue Growth
- RDAC N/A
- SPRO 37.01
- 52 Week Low
- RDAC $10.19
- SPRO $0.83
- 52 Week High
- RDAC $10.31
- SPRO $1.89
- Technical
- Relative Strength Index (RSI)
- RDAC N/A
- SPRO 38.70
- Support Level
- RDAC N/A
- SPRO $0.83
- Resistance Level
- RDAC N/A
- SPRO $1.13
- Average True Range (ATR)
- RDAC 0.00
- SPRO 0.07
- MACD
- RDAC 0.00
- SPRO -0.01
- Stochastic Oscillator
- RDAC 0.00
- SPRO 26.67
About RDAC RISING DRAGON ACQUISITION CORP
Rising Dragon Acquisition Corp is a blank check company.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.